Society for NeuroOncology Annual Meeting | Conferences

Palbociclib Shows Activity, Tolerability in Patients With Brain Metastases Harboring CDK Pathway Alterations

November 25, 2019

The CDK4/6 inhibitor palbociclib (Ibrance) demonstrated it was active and well-tolerated in a phase II interim analysis of patients with brain metastases harboring alterations in the CDK pathway, according to a presentation at the 24th Annual Meeting and Education Day of the Society of NeuroOncology.

For Patients With Neurofibromatosis Type 1, Many Unmet Needs Remain

November 25, 2019

A large proportion of children diagnosed with neurofibromatosis type 1-related plexiform neurofibromas have no appropriate treatment available to them and represent a significant unmet medical need. To determine demographics, clinical characteristics, and treatments, a cross-sectional analysis of existing data from the Children’s Tumor Foundation registry was undertaken by Jinghua He, PhD, MPH, and colleagues.

Palbociclib Shows Promise for Treatment of Brain Metastases Harboring CDK Alterations

November 24, 2019

An interim analysis of the phase II study of palbociclib for the treatment of patients with brain metastases harboring CDK alterations was presented at the 2019 Society for NeuroOncology Annual Meeting by Priscilla K. Brastianos, MD, director of the central nervous system brain metastasis program, Massachusetts General Hospital.

Dabrafenib, Trametinib Combination Shows Response and Duration in BRAF V600E Mutated Tumors

November 24, 2019

Patients with both high-grade and low-grade glioma harboring the BRAF V600E mutation demonstrated positive benefit in response, duration of response, and progression-free survival when given the combination of dabrafenib and trametinib in a phase IIa study.

Veliparib Is Well Tolerated When Added to Standard Treatment in Unmethylated MGMT Glioblastoma Multiforme

November 23, 2019

Adding the PARP inhibitor veliparib to standard therapy for newly diagnosed patients with unmethylated MGMT glioblastoma multiforme was well-tolerated in a phase II trial, according to findings presented at the 24th Annual Meeting and Education Day of the Society of NeuroOncology.

Nivolumab Combinations Feasible for Newly Diagnosed GBM

November 20, 2016

The PD-1 inhibitor nivolumab was successfully combined with radiotherapy alone or concurrently with temozolomide for patients with newly-diagnosed glioblastoma multiforme in cohorts 1c and 1d from the phase I CheckMate-143 study.